C5 and paroxysmal nocturnal hemoglobinuria: Additionally, some patients with PNH treated with eculizumab may experience “breakthrough hemolysis” (BTH) either related to incomplete C5 inhibition (IncC5Inhib) by eculizumab or linked to a complement-amplifying condition (CAC) such as an infection, surgery, or pregnancy.